Quinoline-2-carboxylic acid isolated from Ephedra pachyclada and its structural derivatives show inhibitory effects against α-glucosidase and α-amylase

The aim of present study was to isolate a bioactive compound from the chloroform fraction of Ephedra pachyclada stems and to evaluate antidiabetic activities against α-glucosidase and α-amylase. According to various chromatographic and spectroscopic analyses, the bioactive compound of E. pachyclada...

Full description

Saved in:
Bibliographic Details
Published inApplied biological chemistry Vol. 57; no. 4; pp. 441 - 444
Main Authors Lee, Hwa-Won, Yang, Ji-Yeon, Lee, Hoi-Seon
Format Journal Article
LanguageEnglish
Published Seoul The Korean Society for Applied Biological Chemistry 01.08.2014
Springer Nature B.V
한국응용생명화학회
Subjects
Online AccessGet full text
ISSN1738-2203
2468-0834
2234-344X
2468-0842
DOI10.1007/s13765-014-4156-3

Cover

Loading…
More Information
Summary:The aim of present study was to isolate a bioactive compound from the chloroform fraction of Ephedra pachyclada stems and to evaluate antidiabetic activities against α-glucosidase and α-amylase. According to various chromatographic and spectroscopic analyses, the bioactive compound of E. pachyclada was identified as quinoline-2-carboxylic acid. Based on the IC 50 values of quinoline-2-carboxylic acid derivatives against α-glucosidase and α-amylase, quinoline-2-carboxylic acid (9.1 and 15.5 μg/mL) exhibited potent inhibitory activities, followed by quinoline-3-carboxylic acid (10.6 and 31.4 μg/mL), quinoline-4-carboxylic acid (60.2 and 152.4 μg/mL), and acarbose (66.5 and 180.6 μg/mL) against α-glucosidase and α-amylase, respectively. However, quinoline-2-carboxaldehyde, quinoline-3-carboxaldehyde, and quinoline-4-carboxaldehyde showed no inhibitory activities. Antidiabetic activity depended on the existence of a carboxyl group on quinoline for activities against α-glucosidase and α-amylase. Therefore, E. pachyclada and quinoline-2-carboxylic acid derivatives could be suitable as alternative synthetic antidiabetic agents.
Bibliography:SourceType-Scholarly Journals-1
content type line 14
ObjectType-Editorial-2
ObjectType-Commentary-1
G704-000111.2014.57.4.007
ISSN:1738-2203
2468-0834
2234-344X
2468-0842
DOI:10.1007/s13765-014-4156-3